WO2007066017A3 - Procede de preparation d'un concentre de facteur h et utilisation de ce concentre de facteur h au titre de medicament - Google Patents

Procede de preparation d'un concentre de facteur h et utilisation de ce concentre de facteur h au titre de medicament Download PDF

Info

Publication number
WO2007066017A3
WO2007066017A3 PCT/FR2006/002693 FR2006002693W WO2007066017A3 WO 2007066017 A3 WO2007066017 A3 WO 2007066017A3 FR 2006002693 W FR2006002693 W FR 2006002693W WO 2007066017 A3 WO2007066017 A3 WO 2007066017A3
Authority
WO
WIPO (PCT)
Prior art keywords
factor
drug
concentrate
preparing
uhs
Prior art date
Application number
PCT/FR2006/002693
Other languages
English (en)
Other versions
WO2007066017A2 (fr
Inventor
Sami Chtourou Abdessatar
Claudine Mazurier
Michel Poulle
Bernadette Cauvin
Frederic Dhainault
Original Assignee
Lab Francais Du Fractionnement
Sami Chtourou Abdessatar
Claudine Mazurier
Michel Poulle
Bernadette Cauvin
Frederic Dhainault
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Francais Du Fractionnement, Sami Chtourou Abdessatar, Claudine Mazurier, Michel Poulle, Bernadette Cauvin, Frederic Dhainault filed Critical Lab Francais Du Fractionnement
Priority to JP2008543870A priority Critical patent/JP2009518368A/ja
Priority to AU2006323849A priority patent/AU2006323849B2/en
Priority to EP06841898A priority patent/EP1962885A2/fr
Priority to CA002633102A priority patent/CA2633102A1/fr
Priority to BRPI0619728-0A priority patent/BRPI0619728A2/pt
Priority to US12/095,949 priority patent/US20080318841A1/en
Publication of WO2007066017A2 publication Critical patent/WO2007066017A2/fr
Publication of WO2007066017A3 publication Critical patent/WO2007066017A3/fr
Priority to IL191931A priority patent/IL191931A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne l'utilisation de Facteur H pour la fabrication d'un médicament destiné au traitement du Syndrome Hémolytique Urémique (SHU), un procédé de purification du Facteur H à partir de plasma frais congelé et le concentré de facteur H obtenu par ce procédé.
PCT/FR2006/002693 2005-12-07 2006-12-07 Procede de preparation d'un concentre de facteur h et utilisation de ce concentre de facteur h au titre de medicament WO2007066017A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2008543870A JP2009518368A (ja) 2005-12-07 2006-12-07 因子ｈ濃縮物の調製方法及び薬剤の形でのその使用
AU2006323849A AU2006323849B2 (en) 2005-12-07 2006-12-07 Method for preparing a factor H concentrate and the use thereof in the form of a drug
EP06841898A EP1962885A2 (fr) 2005-12-07 2006-12-07 Procede de preparation d'un concentre de facteur h et utilisation de ce concentre de facteur h au titre de medicament
CA002633102A CA2633102A1 (fr) 2005-12-07 2006-12-07 Procede de preparation d'un concentre de facteur h et utilisation de ce concentre de facteur h au titre de medicament
BRPI0619728-0A BRPI0619728A2 (pt) 2005-12-07 2006-12-07 método de preparação de um concentrado de fator h e utilização deste concentrado de fator h a tìtulo de medicamento
US12/095,949 US20080318841A1 (en) 2005-12-07 2006-12-07 Method For Preparing a Factor H Concentrate and the Use Thereof in the Form of a Drug
IL191931A IL191931A0 (en) 2005-12-07 2008-06-03 Method for preparing a factor h concentrate and the use thereof in the form of a drug

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0512404 2005-12-07
FR0512404A FR2894145B1 (fr) 2005-12-07 2005-12-07 Utilisation de facteur h du complement a titre de medicament

Publications (2)

Publication Number Publication Date
WO2007066017A2 WO2007066017A2 (fr) 2007-06-14
WO2007066017A3 true WO2007066017A3 (fr) 2007-11-08

Family

ID=36928796

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2006/002693 WO2007066017A2 (fr) 2005-12-07 2006-12-07 Procede de preparation d'un concentre de facteur h et utilisation de ce concentre de facteur h au titre de medicament

Country Status (11)

Country Link
US (1) US20080318841A1 (fr)
EP (1) EP1962885A2 (fr)
JP (2) JP2009518368A (fr)
KR (1) KR20080091441A (fr)
CN (2) CN101336111A (fr)
AU (1) AU2006323849B2 (fr)
BR (1) BRPI0619728A2 (fr)
CA (1) CA2633102A1 (fr)
FR (1) FR2894145B1 (fr)
IL (1) IL191931A0 (fr)
WO (1) WO2007066017A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007038995A1 (fr) 2005-09-19 2007-04-12 Csl Behring Gmbh Facteur h pour le traitement de néphropathies chroniques et sa production
FR2933496B1 (fr) * 2008-07-02 2012-10-05 Lfb Biotechnologies Procede de mesure du taux de facteur vii active dans un echantillon
RS64039B1 (sr) * 2008-11-10 2023-04-28 Alexion Pharma Inc Metode i kompozicije za lečenje poremećaja povezanih sa komplementom
GB0904427D0 (en) 2009-03-13 2009-04-29 Lachmann Peter Treatment of diseases related to hyperactivity of the complement system
US8304524B2 (en) * 2009-07-23 2012-11-06 Baxter International Inc. Manufacture of factor H (FH) and FH-derivatives from plasma
FR2952640B1 (fr) * 2009-11-16 2012-12-07 Lab Francais Du Fractionnement Procede de fabrication d'une preparation de facteur h
FR2952539B1 (fr) 2009-11-16 2012-01-13 Lab Francais Du Fractionnement Preparation d'un concentre de facteur h
WO2011113641A1 (fr) 2010-02-12 2011-09-22 Cemm Forschungszentrum Für Molekulare Medizin Gmbh Facteur h du complément pour états pathologiques de stress oxydatif
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
US8796430B2 (en) 2010-05-26 2014-08-05 Baxter International Inc. Method to produce an immunoglobulin preparation with improved yield
WO2012049245A1 (fr) 2010-10-13 2012-04-19 Octapharma Ag Méthode de purification du facteur h du complément
FR2967071A1 (fr) 2010-11-10 2012-05-11 Lab Francais Du Fractionnement Facteur h pour le traitement de maladies auto-immunes du systeme nerveux
FR2981661B1 (fr) * 2011-10-25 2015-06-19 Lfb Biotechnologies Procede de preparation du facteur h humain
FR2983212A1 (fr) 2011-11-28 2013-05-31 Lfb Biotechnologies Aptameres anti-fh, procede pour leur obtention et utilisations
DK2968457T3 (en) 2013-03-14 2018-10-29 Baxalta Inc FACTOR H FOR TRANSPLANTATION
AU2014236782B2 (en) 2013-03-14 2019-01-03 Baxalta GmbH Factor H for treatment of rheumatoid arthritis
AU2013203048A1 (en) 2013-03-15 2014-10-02 Baxalta GmbH Isolation of factor h from fraction i paste
AU2013202965B2 (en) 2013-03-15 2016-07-21 Takeda Pharmaceutical Company Limited Improved method for producing factor h from a plasma precipitation fraction
US20150079613A1 (en) 2013-08-07 2015-03-19 Ryan Kitchel Atypical hemolytic uremic syndrome biomarker proteins
US10112993B2 (en) * 2014-08-20 2018-10-30 Stichting Sanquin Bloedvoorziening Factor H potentiating antibodies and uses thereof
US11820814B2 (en) 2019-07-17 2023-11-21 Gemini Therapeutics Sub, Inc. Factor H potentiating antibodies and uses thereof
CN113045634B (zh) * 2019-12-28 2023-04-28 四川远大蜀阳药业有限责任公司 一种补体h因子制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4883784A (en) * 1985-11-08 1989-11-28 Sankyo Company Limited Human complement factors and their therapeutic use
WO1998023638A2 (fr) * 1996-11-28 1998-06-04 University Of Leicester Inhibiteur du complement
EP1336618A1 (fr) * 2002-02-15 2003-08-20 HANS-KNÖLL-INSTITUT FÜR NATURSTOFF-FORSCHUNG e.V. Facteur H du complement de porc et son utilisation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1326893A2 (fr) * 2000-10-13 2003-07-16 Octapharma AG Fraction de plasma renfermant de la bikunine, son procede de fabrication et son utilisation
WO2007038995A1 (fr) * 2005-09-19 2007-04-12 Csl Behring Gmbh Facteur h pour le traitement de néphropathies chroniques et sa production

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4883784A (en) * 1985-11-08 1989-11-28 Sankyo Company Limited Human complement factors and their therapeutic use
WO1998023638A2 (fr) * 1996-11-28 1998-06-04 University Of Leicester Inhibiteur du complement
EP1336618A1 (fr) * 2002-02-15 2003-08-20 HANS-KNÖLL-INSTITUT FÜR NATURSTOFF-FORSCHUNG e.V. Facteur H du complement de porc et son utilisation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LUNDWALL A ET AL: "Isolation of human complement factors C3, C5 and H.", JOURNAL OF IMMUNOLOGICAL METHODS 16 JUL 1985, vol. 81, no. 1, 16 July 1985 (1985-07-16), pages 147 - 160, XP002449173, ISSN: 0022-1759 *
MANUELIAN TAMARA ET AL: "Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome.", JOURNAL OF CLINICAL INVESTIGATION, vol. 111, no. 8, April 2003 (2003-04-01), pages 1181 - 1190, XP002397734, ISSN: 0021-9738 *

Also Published As

Publication number Publication date
US20080318841A1 (en) 2008-12-25
JP2009518368A (ja) 2009-05-07
JP2012211189A (ja) 2012-11-01
EP1962885A2 (fr) 2008-09-03
FR2894145B1 (fr) 2008-10-17
WO2007066017A2 (fr) 2007-06-14
BRPI0619728A2 (pt) 2011-10-11
KR20080091441A (ko) 2008-10-13
FR2894145A1 (fr) 2007-06-08
CA2633102A1 (fr) 2007-06-14
AU2006323849B2 (en) 2012-11-01
CN102988958A (zh) 2013-03-27
AU2006323849A1 (en) 2007-06-14
IL191931A0 (en) 2009-02-11
CN101336111A (zh) 2008-12-31

Similar Documents

Publication Publication Date Title
WO2007066017A3 (fr) Procede de preparation d'un concentre de facteur h et utilisation de ce concentre de facteur h au titre de medicament
AU2018260815A1 (en) Treatment of Acute Lymphoblastic Leukemia
WO2006072347A3 (fr) Thiophene substitue par un alkinyle
WO2008046581A3 (fr) Composés tétrahydropyrrolopyrazine substitués et leur utilisation dans des médicaments
SG135037A1 (en) Composite semipermeable membrane, and production process thereof
WO2006127898A3 (fr) (s)-n-methylnaltrexone
WO2007024705A3 (fr) Procede de traitement de la depression au moyen d'un anticorps anti-tnf-alpha
WO2009010877A3 (fr) Purification de conjugués
IL177541A0 (en) A method of providing a purified, virus safe antibody preparation
WO2008127364A3 (fr) Composés antiviraux et utilisation de ceux-ci
EP1982736A4 (fr) Eau servant à préparer un dialysat et dialysat et procédé de production d'un dialysat utilisant celle-ci et dialyseur
EP1820566A4 (fr) Membrane composite semi-perméable et procédé de fabrication de ladite membrane
IL185031A0 (en) Method for the preparation of pregabalin and salts thereof
WO2006072348A3 (fr) Thiophene substitue par un alkinyle
IL172584A (en) Functionally reconstituted viral membranes containing adjuvant and methods for their production
WO2007091266A3 (fr) Alpha-i antitrypsine pour le traitement d'épisodes d'exacerbation de maladies pulmonaires
EP1806174A4 (fr) Procede de fabrication de membrane composite semi-perméable
EP1825905A4 (fr) Membrane composite semi-perméable et procédé de fabrication de ladite membrane
WO2006034035A3 (fr) Traitement de l'ischemie
WO2009130604A3 (fr) Formes à l'état solide de sels de déférasirox et leurs procédés de fabrication
WO2011147797A3 (fr) Composé hybride, son utilisation et son procédé de préparation
WO2007073937A3 (fr) Procede permettant de preparer des formes cristallines de l'orlistat
WO2007120263A3 (fr) Préparation de dutastéride
WO2007115929A8 (fr) Thiazolyl-dihydro-quinazolines
WO2007020448A3 (fr) Procede

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2008543870

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2633102

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 4949/DELNP/2008

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006323849

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020087016073

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006841898

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006323849

Country of ref document: AU

Date of ref document: 20061207

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006323849

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200680052193.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06841898

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12095949

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2006841898

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0619728

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080606